Pages that link to "Q43831725"

The following pages link to Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression (Q43831725):

Displaying 44 items.

• Histone deacetylases (HDACs): characterization of the classical HDAC family (Q24535587) (← links)
• Clinical use and applications of histone deacetylase inhibitors in multiple myeloma (Q26745930) (← links)
• Panobinostat for the treatment of multiple myeloma: the evidence to date (Q26778674) (← links)
• Novel agents for multiple myeloma to overcome resistance in phase III clinical trials (Q26822754) (← links)
• Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells (Q33593796) (← links)
• Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids (Q33747841) (← links)
• High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. (Q33842759) (← links)
• The DAC system and associations with multiple myeloma. (Q34414447) (← links)
• Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29 (Q34576966) (← links)
• The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma (Q34602263) (← links)
• Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype (Q35595410) (← links)
• MicroRNAs: New Players in Multiple Myeloma (Q35711092) (← links)
• Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress (Q35750893) (← links)
• Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma (Q35910526) (← links)
• Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells (Q36512713) (← links)
• MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies (Q36602853) (← links)
• Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy (Q36763539) (← links)
• Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. (Q37083880) (← links)
• Glucose metabolism as a target of histone deacetylase inhibitors. (Q37125470) (← links)
• Gene modulation associated with inhibition of liver regeneration in hepatitis B virus X transgenic mice (Q37189594) (← links)
• Caveolin induces cardioprotection through epigenetic regulation (Q37294656) (← links)
• The emerging role of lysine acetylation of non-nuclear proteins (Q37676974) (← links)
• Panobinostat for the treatment of multiple myeloma (Q37992104) (← links)
• Epigenetic modulating agents as a new therapeutic approach in multiple myeloma (Q38161731) (← links)
• Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids (Q38569361) (← links)
• Epigenetics in Multiple Myeloma. (Q38970577) (← links)
• The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway (Q39113061) (← links)
• Resistance of mitochondrial p53 to dominant inhibition (Q39597902) (← links)
• The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells (Q39658232) (← links)
• Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma (Q40341141) (← links)
• Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma (Q40396320) (← links)
• 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. (Q40479015) (← links)
• Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo (Q40501526) (← links)
• Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma (Q40520464) (← links)
• Acetylation of histone H3 at lysine 9 by ethanol in rat hepatocytes (Q44476757) (← links)
• Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway (Q44512459) (← links)
• Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes (Q44555704) (← links)
• The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells (Q45309583) (← links)
• Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma (Q46192240) (← links)
• Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma (Q47339184) (← links)
• DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. (Q52676395) (← links)
• The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. (Q54539131) (← links)
• Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner (Q91756067) (← links)
• Histone deacetylase inhibitors in multiple myeloma (Q93541719) (← links)